Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
12/01/2026 12:40
Jan 12 (Reuters) - Cabaletta Bio Inc CABA.O: IND AMENDMENT CLEARANCE OBTAINED FOR CLINICAL MANUFACTURING OF RESE-CEL FROM CABALETTA BIO USING CELLARES' AUTOMATED PLATFORMS Source text: ID:nBw7rLTWva Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity